CD8A and acute lymphoblastic leukemia: Analysis of fractional shortening showed similar results (Fig. 2D–E), with a significant decrease between E1 and E2 for the PBS (−4 ± 3%), the CD8 (−4 ± 3%) and the ALL (−7 ± 6%) groups, but a stabilization for the SPEC treatment group (+1 ± 5%).